Manufacturing

Feliza Mirasol is the science editor for 

Articles

Synthego has opened its new GMP-compliant RNA manufacturing facility in Redwood City, Calif., for CRISPR-enabled genomics therapeutics.

Synthego Launches New RNA Manufacturing Facility

Jeong Jin-hyeok is principal scientist in drug product at Samsung Biologics.

To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.

Preparing for a New Wave of mRNA Technologies

The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.


Ramping Up Nucleic Acid Therapy Development

The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.

Ramping Up Development of Nucleic Acid Therapies 

Mark Rogers, PhD, mark.rogers@sgs.com, is the global scientific director for the SGS Health Science Drug Development group. He  has been with SGS for nearly 8 years since joining the company via an acquisition (M-Scan) in 2010. Rogers received his PhD in analytical chemistry from Westminster University in 1985 and has over 35 peer-reviewed publications, including Nature, and one patent. His post-doctoral work, at Imperial College, London, was followed by a lectureship in the endocrinology department at St. Mary’s hospital specializing in diabetes. Rogers then went on to join M-Scan, USA in 1990 where he remained as vice-president until its acquisition by SGS. Since joining SGS he has had several roles including, head of North American Biologics, vice-president of SGS USA, and today, he is the Global Scientific director for the SGS Health Science Drug Development group.

Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.

The Marriage of RNA and Mass Spectrometry

Agilent’s therapeutic nucleic acids facility gains architectural design support from CRB.

Agilent Gains Design Support from CRB for Manufacturing Facility Expansion

Pfizer and Touchlight have signed a patent license agreement for Pfizer to use Touchlight’s doggybone DNA (dbDNA) in the manufacture of mRNA vaccines, therapeutics, and gene therapies.

Pfizer and Touchlight Enter Patent License Agreement for Use of dbDNA

Wacker is investing more than €100 million (US$100.5 million) to expand its Halle, Germany, site with an mRNA competence center.

Wacker Biotech Expands Germany Site with Construction of New mRNA Competence Center

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

Avantor and Cytovance Biologics Partner on Plasmid DNA Development

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

Manufacturing, Nucleic Acids